GlycoMimetics Debt to Equity Ratio 2012-2025 | CBIO
Current and historical debt to equity ratio values for GlycoMimetics (CBIO) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. GlycoMimetics debt/equity for the three months ending March 31, 2025 was 0.00.
| GlycoMimetics Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2025-03-31 |
$0.00B |
$0.00B |
0.78 |
| 2024-12-31 |
$0.01B |
$0.01B |
1.09 |
| 2024-09-30 |
$0.00B |
$0.01B |
0.38 |
| 2024-06-30 |
$0.00B |
$0.02B |
0.22 |
| 2024-03-31 |
$0.01B |
$0.03B |
0.18 |
| 2023-12-31 |
$0.01B |
$0.04B |
0.18 |
| 2023-09-30 |
$0.01B |
$0.05B |
0.14 |
| 2023-06-30 |
$0.01B |
$0.06B |
0.13 |
| 2023-03-31 |
$0.01B |
$0.06B |
0.11 |
| 2022-12-31 |
$0.01B |
$0.04B |
0.21 |
| 2022-09-30 |
$0.01B |
$0.05B |
0.16 |
| 2022-06-30 |
$0.01B |
$0.06B |
0.17 |
| 2022-03-31 |
$0.01B |
$0.07B |
0.20 |
| 2021-12-31 |
$0.01B |
$0.08B |
0.16 |
| 2021-09-30 |
$0.01B |
$0.10B |
0.12 |
| 2021-06-30 |
$0.01B |
$0.11B |
0.11 |
| 2021-03-31 |
$0.01B |
$0.13B |
0.10 |
| 2020-12-31 |
$0.02B |
$0.13B |
0.11 |
| 2020-09-30 |
$0.01B |
$0.14B |
0.09 |
| 2020-06-30 |
$0.01B |
$0.15B |
0.09 |
| 2020-03-31 |
$0.01B |
$0.15B |
0.09 |
| 2019-12-31 |
$0.01B |
$0.15B |
0.09 |
| 2019-09-30 |
$0.01B |
$0.17B |
0.08 |
| 2019-06-30 |
$0.01B |
$0.18B |
0.08 |
| 2019-03-31 |
$0.01B |
$0.19B |
0.06 |
| 2018-12-31 |
$0.01B |
$0.21B |
0.05 |
| 2018-09-30 |
$0.01B |
$0.22B |
0.03 |
| 2018-06-30 |
$0.01B |
$0.23B |
0.03 |
| 2018-03-31 |
$0.01B |
$0.24B |
0.04 |
| 2017-12-31 |
$0.01B |
$0.12B |
0.07 |
| 2017-09-30 |
$0.01B |
$0.11B |
0.07 |
| 2017-06-30 |
$0.01B |
$0.12B |
0.05 |
| 2017-03-31 |
$0.01B |
$0.03B |
0.17 |
| 2016-12-31 |
$0.01B |
$0.04B |
0.20 |
| 2016-09-30 |
$0.01B |
$0.04B |
0.15 |
| 2016-06-30 |
$0.01B |
$0.05B |
0.14 |
| 2016-03-31 |
$0.01B |
$0.04B |
0.17 |
| 2015-12-31 |
$0.01B |
$0.04B |
0.20 |
| 2015-09-30 |
$0.01B |
$0.05B |
0.14 |
| 2015-06-30 |
$0.01B |
$0.06B |
0.12 |
| 2015-03-31 |
$0.00B |
$0.04B |
0.09 |
| 2014-12-31 |
$0.01B |
$0.05B |
0.13 |
| 2014-09-30 |
$0.01B |
$0.06B |
0.08 |
| 2014-06-30 |
$0.00B |
$0.06B |
0.06 |
| 2014-03-31 |
$0.00B |
$0.06B |
0.05 |
| 2013-12-31 |
$0.00B |
$0.00B |
0.82 |
| 2013-09-30 |
$0.00B |
$0.01B |
0.47 |
| 2013-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2013-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2012-12-31 |
$0.00B |
|
0.00 |
| 2012-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2011-12-31 |
$0.02B |
$0.01B |
2.42 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.009B |
$0.000B |
|
GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States.
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
| OncoCyte (IMDX) |
United States |
$0.090B |
0.00 |
